Geron Corporation announced a strategic restructuring plan that will reduce its workforce by approximately one-third of its current 260 employees, resulting in approximately 87 job cuts. The biopharmaceutical company aims to reduce 2026 operating expenses below 2025 levels, with savings expected to begin in Q1 2026. The company's stock has declined nearly 64% year-to-date